10M
Cancer deaths worldwide
WHO estimated nearly 10 million cancer deaths globally in 2024.
Global data center
Cancer statistics make more sense when the limits are visible.
A plain-language starting point for cancer prevalence, mortality, costs, treatment access, and barriers around the world.
38%
Potentially preventable
WHO estimates this share can be prevented with current prevention strategies.
185
Countries in GLOBOCAN
IARC publishes estimates for 36 cancer types across 185 countries.
$21B
U.S. patient burden
NCI reported 2019 U.S. patient out-of-pocket plus time costs above $21 billion.
What this page should grow into
A useful worldwide statistics center should answer more than which cancers are common. It should connect burden, cost, treatment access, and barriers to care.
Cancer statistics are best read as maps, not personal predictions. They can show where prevention, screening, diagnosis, treatment, and palliative care are reaching people, and where systems are leaving people behind.
Official global estimates also have limits. Some countries have strong cancer registries, while others depend more heavily on modeled estimates. A fair comparison should say when a number is measured, estimated, old, incomplete, or affected by underdiagnosis.
- Cancer incidence, mortality, and prevalence by cancer type, country, age, and sex.
- Where data supports it, patterns by race, ethnicity, income, rural access, insurance status, or other equity measures.
- Treatment availability by setting: surgery, radiation therapy, pathology, essential medicines, palliative care, and clinical trials.
- Real-world barriers such as travel distance, drug cost, shortages, late diagnosis, stigma, conflict, language, and missing cancer registries.
Numbers that need context
A high cancer rate can mean more risk, better detection, older population age, stronger registries, or some mix of all of those. Mortality may reflect biology, stage at diagnosis, treatment access, and follow-up care.
That is why this page should pair every chart with plain-language notes. A breast cancer rate, for example, can reflect screening access and registry strength as much as underlying biology. A survival comparison can reflect stage at diagnosis, treatment availability, follow-up time, and how deaths are recorded.
Costs need the same caution. Patient costs, insurer payments, public spending, lost wages, travel, caregiver time, and national economic burden are different measurements. They should not be collapsed into one scary number without explaining what is counted.
Better comparisons to build next
The next step is to turn this into a filterable, source-linked data room. The most useful version would let people compare one cancer type across countries without losing the human context behind the table.
For low-resource settings, the page should also say when public data is thin. Missing data can be a sign of missing registry capacity, not missing cancer. The tone matters: the goal is to describe barriers and needs without treating whole countries as a problem to be solved from the outside.
- Cancer treatment cost by cancer type, with separate views for patient costs and health-system costs when sources allow it.
- Treatment effectiveness and survival summaries that state stage, biomarker, country, and treatment era instead of treating cancer as one disease.
- Low-resource country pages that explain what information is missing and where official data is limited.
- Plain-language data notes so readers know when a chart is measured, estimated, modeled, old, or incomplete.
Related places on Cancer Explained
Sources used for this page
WHO Cancer fact sheetGlobal cancer burden, prevention, treatment access, and palliative care context.IARC Global Cancer ObservatoryInternational estimates for incidence, mortality, and prevalence.NCI: Managing Cancer CostsPlain-language guidance on treatment costs and insurance questions.NCI Annual Report economic burden releaseU.S. patient out-of-pocket and time-cost estimates.